INTRODUCTION AND OBJECTIVES: BAP1 is a ubiquitin carboxy-terminal hydrolase enzyme (UCH) which along with the ASXL1/2 protein forms the PR-DUB, chromatin associated complex which removes monoubiquitin from H2A in nucleosomes regulating gene expression. BAP1 is a tumor suppressor gene commonly mutated gene in clear cell renal cell carcinoma (ccRCC) and other cancers such as uveal melanoma (UM) and mesothelioma. In tumors, BAP1 mutations occur throughout the protein well outside the N-terminal UCH catalytic region while C-terminal BAP1 truncations/mutations in the ULD domain also inactivate BAP. The aim of this study was to investigate the potential mechanisms whereby these highly spatially distinct mutations in BAP1, many of which occur outside the UCH catalytic domain, serve to completely inactivate the enzyme function. We focused on BAP1s obligate partner protein ASXL1/2 which binds the BAP1 ULD domain and may exert a global regulatory function in the context of PR-DUB in chromatin. A mechanistic understanding of these events might provide insight towards restoration of normal BAP1 functions in tumors leading to therapeutic benefit. METHODS: BAP1 mutations derived from multiple tumor types were identified, including UM, Mesothelioma and ccRCC and introduced into expression vectors and the proteins expressed as recombinants in e.coli and purified to homogeneity. BAP1 and ASXL1/2 protein complexes were evaluated for protein interaction and UCH enzyme activity using GST-interaction studies, Western blot and gel filtration analysis. Molecular modeling of the complex was performed by Blast analysis, molecular docking methods and refined using insights from our mutagenic study.
RESULTS: This structure-function study revealed that the BAP1 and ASXL1/2 is direct, high affinity and that multiple contact points between BAP1, ASXL1/2 exist that stabilize the native catalytic structure the The domain structure of BAP1 is unique, multi-lobed and seems to be highly allosteric with respect to enzyme activation. ASXL1/ 2 is an obligate partner for BAP1 and the enzyme is dead with out ASXL1/2 binding which occurs in the BAP1 ULD domain: many tumor derived mutants in the BAP1 ULD domain disrupt ASXL1/2 binding and abolish BAP1 activity. We also discovered a highly conserved domain in ASXL1/2 as minimally essential for BAP1 binding and activation. Mutations in multiple tumors at widely scattered locations decreased ubiquitin hydrolase activity in re-constituted protein complexes and destabilized binding of BAP1 and ASXL1/2 upon modeling.
CONCLUSIONS: Different mutations derived from multiple tumors occur throughout the sequence of BAP1 and apparently act allosterically to alter the ability of ASXL1/2 to both bind and/or interact unproductively with the BAP1 UCH region which leads to loss of enzymatic activity and loss of tumor suppression. This analysis suggests that small molecule approaches might be used to reactivate the latent UCH activity in some tumors and restore wild type function of BAP1.
INTRODUCTION AND OBJECTIVES:
Collecting duct carcinoma (CDC) and renal medullary carcinoma (RMC) represent rare tumors that arise in the renal medulla and are therapy resistant with rapid progression. The objective of this study is to better define the genomic profile of these tumors.
METHODS: DNA was extracted from 40 microns of FFPE specimen from refractory CDC (46 cases) and RMC (24 cases). CGP was performed using a hybrid-capture, adaptor ligation based next generation sequencing assay to a mean coverage depth of >800X. Tumor mutational burden (TMB) was calculated from a minimum of 1.11 Mb of sequenced DNA as previously described and reported as mutations/Mb. Microsatellite instability status (MSI) was determined on 114 loci.
RESULTS: All CDC patients were older and more frequently male (Table 1) . Sickle cell trait was identified in both CDC and RMC, but far more frequently associated with RMC. All (100%) of CDC and RMC were clinically advanced Stage III and IV tumors with the primary tumor used for CGP in 70% of cases and a metastasis biopsy was sequenced in 30%. All (100%) CDC and RMC were intermediate (Grade 3) or high grade (Grade 4). In both tumor types, the rate of genetic alteration (GA) was relatively low and there were no (0%) VHL GA. SMARCB1 GA were significantly more frequent in RMC than CDC, but common in both tumors. Targeted therapies for kinase (EGFR, RET) and MTOR (NF2, TSC2) pathways were more frequent in CDC than RMC. At 1.8 mut/Mb, the median TMB was low for both tumor types with no (0%) cases showing ¼ 20 mut/Mb. None (0%) of the CDC or RMC cases featured MSI-high status.
CONCLUSIONS: In addition to their histologic differences, the frequencies and types of GA seen in CDC differ significantly from that seen in RMC. The opportunities for biomarker driven targeted therapies for both CDC and RMC appear limited with rare opportunities to target GA in TKGFR and MTOR pathways for CDC. Similarly, the relatively low TMB and absence of MSI-High status in CDC and RMC also predicts that these tumors may be resistant to immunotherapies.
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